TIDMPOLB
RNS Number : 2623S
Poolbeg Pharma PLC
03 November 2023
Poolbeg Pharma plc
POLB 001 Data to be Presented at American Society of Hematology
Annual Meeting
Potential to address cancer treatment related Cytokine Release
Syndrome
3 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company targeting diseases with a high unmet medical need,
announces that an abstract detailing POLB 001's promise as a
potential treatment for Cytokine Release Syndrome associated with
cancer immunotherapies has been accepted for presentation at 65th
American Society of Hematology ('ASH') Annual Meeting and
Exposition, to be held 9-12 December 2023 in San Diego,
California.
The ASH Annual Meeting and Exposition is recognised as the
world's premier conference focussing on haematological malignancies
(blood cancers) and brings together over 25,000 industry and
academic attendees each year to share the latest scientific
discoveries and advances in clinical care.
Poolbeg's poster presentation will provide insight into the
results obtained from the POLB 001 LPS human challenge trial,
highlighting its potential use in the treatment of Cytokine Release
Syndrome (CRS) associated with severe influenza and cancer
immunotherapies. Mild to moderate cases of CRS require
hospitalisation and can impact the ability to deliver the cancer
immunotherapies, severe cases of CRS can become life-threatening
and may require intensive care, and in rare cases cause mortality.
An effective therapy for CRS associated with cancer immunotherapies
has the potential to make these treatments more tolerable for
individual patients to enable them to best benefit from their
treatment and to make cancer immunotherapies more widely
accessible.
Title: POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with
the Potential to Prevent Cytokine Release Syndrome (CRS)
Session Name: 704. Cellular Immunotherapies: Early Phase and
Investigational Therapies: Poster I
Session Date: Saturday, December 9, 2023
Presentation Time: 5:30 PM - 7:30 PM
Presenter: Dr Emma Searle, Consultant Hematologist and Honorary
Senior Lecturer at University of Manchester
Location: San Diego Convention Center, Halls G-H
Dr Emma Searle, Consultant Hematologist and Honorary Senior
Lecturer at University of Manchester, said: "Having this abstract
accepted at ASH represents a strong validation of POLB 001's
potential in addressing CRS in oncology. Cytokine Release Syndrome
is highly prevalent among patients receiving immunotherapy for
haematological malignancies. The positive data from the LPS
challenge trial has highlighted that oral treatment of POLB 001
holds great promise in tackling this issue; potentially leading to
improved patient outcomes, reduced strain on healthcare systems
while making these treatments more accessible to a broader patient
population."
If you would like to meet with Poolbeg Pharma to discuss POLB
001, get in touch: partnering@poolbegpharma.com
Investor Meet Company Presentation
Poolbeg will be hosting a meeting for investors and analysts on
the POLB 001 Oncology Programme on Monday 6
November 2023 at 2:00pm - 3:30pm GMT via the Investor Meet Company platform .
The presentation is open to all existing and potential
shareholders. Questions can be submitted in advance via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet for free and add Poolbeg
Pharma plc to their company dashboard via:
https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and utilising its licensed Oral Delivery Platform to
target metabolic conditions.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESUPGCUGUPWPUP
(END) Dow Jones Newswires
November 03, 2023 03:05 ET (07:05 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024